Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085063 | 0.92 | KMO (0.46) | KMOKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL1085376 | 0.86 | XDH (0.56) | KMOKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL1420936 | 0.84 | KMO (0.53) | KMOKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL1085249 | 0.81 | KMO (0.43) | KMOKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL14931879 | 0.81 | KMO (0.55) | KMOKDM4EALDH1A1XDHSMN1; SMN2 | |
| SCHEMBL1422385 | 0.80 | PIN1 (0.44) | KMOKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL1421332 | 0.79 | MAPT (0.51) | KMOKDM4EMAPTALDH1A1XDH | |
| SCHEMBL1083730 | 0.78 | ACACB (0.47) | — | |
| SCHEMBL1085143 | 0.77 | AKR1C3 (0.50) | KDM4ENPSR1ALDH1A1XDHSMN1; SMN2 | |
| SCHEMBL1085229 | 0.76 | KDM4E (0.42) | KMOKDM4ELMNAMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8153805-B2 | Biaryl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2297137-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2205583-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009043747-A2 | N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-09 | — | — | WO | disclosed |
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048238-A1 | NOVEL BIARYL DERIVATIVES | CCR3, CCRL2, CCR2 | KMO 1845/4885KDM4E 3999/4885LMNA 3998/4885 |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | CCR3, CCR2, CCR1 | KMO 1922/4885KDM4E 2222/4885LMNA 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.